<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>255</serviceExecutionTime><Trial id="195575"><TitleDisplay>Dietary Intervention for Visceral Adiposity</TitleDisplay><TitleOfficial>Dietary Intervention for Visceral Adiposity-Pilot</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01350518</Identifier><Identifier type="Organisational Study">00579</Identifier><Identifier type="Other">IRB00013678</Identifier><Identifier type="Trial Acronym">DIVA-Pilot</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="172" role="Therapeutic effect marker" type="Genomic;Proteomic">Adiponectin</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2197" role="Therapeutic effect marker" type="Biochemical">Vitamin D</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="16296" role="Therapeutic effect marker" type="Proteomic">Ghrelin-28</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName><BiomarkerName id="19632" role="Therapeutic effect marker" type="Structural (imaging)">Abdominal fat</BiomarkerName><BiomarkerName id="24537" role="Therapeutic effect marker" type="Proteomic">Adipokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Benefiber</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>TrueLemon</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nutritional education</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1158032" type="Company"><TargetEntity id="5013268180" type="organizationId">Wake Forest University Health Sciences</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1158032">Wake Forest University Health Sciences, US</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>African Ancestry</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2011-02-28T00:00:00Z</DateStart><DateEnd type="actual">2014-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T02:37:45Z</DateChangeLast><DateAdded>2014-06-12T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Wake Forest Unversity Health Sciences</Affiliation><Name>Kristen G Hairston, MD MPH</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Pre-menopausal&lt;/li&gt;&lt;li&gt;Self-identified as an African-American woman&lt;/li&gt;&lt;li&gt;Aged 20 to 50 years&lt;/li&gt;&lt;li&gt;Willing  and able to provide informed consent&lt;/li&gt;&lt;li&gt;No contraindication to weight loss&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diabetes or currently taking medication to lower blood sugar&lt;/li&gt;&lt;li&gt;Currently on lipid lowering medications&lt;/li&gt;&lt;li&gt;Currently taking chronic steroids&lt;/li&gt;&lt;li&gt;Current diagnosis of kidney or heart failure&lt;/li&gt;&lt;li&gt;Untreated hypothyroidism or hyperthyroidism&lt;/li&gt;&lt;li&gt;BMI&amp;lt; 30 kg/m2 or waist circumference &amp;lt; 88 cm&lt;/li&gt;&lt;li&gt;Current fiber supplementation&lt;/li&gt;&lt;li&gt;Current pregnancy&lt;/li&gt;&lt;li&gt;Body mass&amp;gt; 140 kg (CT limit)&lt;/li&gt;&lt;li&gt;Inability to speak or read English&lt;/li&gt;&lt;li&gt;Gastrointestinal disorders that prohibit the increased consumption of fiber&lt;/li&gt;&lt;li&gt;Current participation in a structured weight loss/diet intervention program&lt;/li&gt;&lt;li&gt;Inability to consume artificial sweeteners&lt;/li&gt;&lt;li&gt;Inability or unwillingness to travel to the CRU during operating hours at the required frequency&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in abdominal adiposity measured by CT: change in area of three abdominal fat depots, namely visceral,subcutaneous and liver fat</Description><Timeframe>12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in metabolic risk factors: glucose, insulin, lipids, inflammatory markers, adipokines, blood pressure, BMI, 25-OH vitamin D</Description><Timeframe>12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this research study was to determine whether increased intake of dietary fiber      during a 12-week, low-calorie weight loss intervention affects abdominal fat change and      improves cardiovascular risk factors in African-American women more than a standard weight      loss intervention.&lt;/para&gt;&lt;para&gt;The specific aims of the study were:&lt;br/&gt;To test, in a small clinical trial of 30 pre-menopausal African American      women, whether increased intake of dietary fiber embedded in a 12 week weight loss      intervention would reduce VAT accumulation more than a standard weight loss intervention.&lt;br/&gt;To test, in a small clinical trial of 30 pre-menopausal African American      women, whether increased intake of dietary fiber embedded in a 12 week weight loss      intervention would improve cardiovascular risk factors more than a standard weight loss      intervention.&lt;br/&gt;To characterize investigator's ability to recruit and retain 30 African-American,      premenopausal women to a 12 week weight loss intervention study.&lt;br/&gt;To determine subject compliance with serum and other measurement      evaluations and dietary compliance logs.&lt;/para&gt;&lt;para&gt;The investigators would test  two main hypothesis:&lt;br/&gt;Hypothesis 1: women in the high dietary fiber intervention group would lose significantly      more abdominal fat around their organs than women in the standard fiber group.&lt;br/&gt;Hypothesis 2: women in the high dietary fiber intervention group would have lower blood      pressure, fasting glucose, fasting lipids and inflammatory factors at 3 months compared to      women in the control group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of four arms:&lt;br/&gt;Arm A: subjects would receive study prepared meals and placebo dietary supplement packet contains 8 g of Splenda and 3 g of TRUE Lemon sweetener. Each packet would be designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid oz. Subjects would not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.&lt;br/&gt;Arm B: subjects would receive nutritional counseling with three supplement packets of Benefiber per day. Subjects receiving nutritional education would have two individual sessions (spaced approximately 2 weeks apart). The nutritional sessions would focus on knowledge, self-regulation, motivation, experience and environment. Subjects would receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .&lt;br/&gt;Arm C: subjects would receive nutrition counseling and placebo. Each placebo dietary supplement packet contains 8 g of Splenda and 3 g of TRUE Lemon sweetener. Each packet was designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid oz. Subjects would receive no fiber supplementation in their TrueLemon mixture.&lt;br/&gt;Arm D: subjects would receive study prepared meals  and Bene powder.  Subjects would receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.&lt;/para&gt;&lt;para&gt;All subjects would have a daily caloric restriction of 800 kcal in order to facilitate      a loss of 0.5 to 0.9 kg/week weight loss or a 9 to 18 kg loss during the 12-week study      period.  All subjects would undergo a resting metabolic rate determination using      MedGraphics Ultima metabolic cart and the accompanying Breeze software. Based on the      caloric need determined to maintain weight, a new caloric plan, 800 kcal lower than basal      needs, would be determined. At minimum, however, all women would receive 1000 kcal/day.      Once caloric goals were determined, these would be achieved with through CRU-prepared meal      replacements or subject- instituted calorie restriction techniques learned via      nutritional education group sessions.&lt;/para&gt;&lt;para&gt;Subjects receiving nutritional education would two individual sessions (spaced approximately 2      weeks apart).  The nutritional sessions would focus on knowledge, self-regulation,      motivation, experience and environment.&lt;br/&gt;All subjects would be weighed at baseline and then weekly until the close of the study,      week 13.  Additionally, all subjects would, with CRU-prepared meals, be asked to return      uneaten food, record any foods eaten that were not part of the plan and complete weekly food      compliance logs. Subjects with self-directed food selection after nutritional education      would be asked to completed detailed records of foods selected each day. All logs and food      records would be reviewed by the PI and the CRU study dietician. If subjects have:  increased weight by  &gt;/=  5 lb between weigh-in sessions; a trend of weight gain for two      consecutive sessions; or failed to return two consecutive food logs; they would be flagged      for additional nutritional counseling.&lt;/para&gt;&lt;para&gt;The primary outcome, change in VAT between baseline and 12 weeks,      would be obtained via repeat computed tomography (CT) scans. The secondary outcomes were      change in CVD risk factors (blood pressure, fasting lipids, insulin sensitivity, C-reactive      protein) and liver attenuation. Abdominal fat mass would be measured at the L4/L5 vertebral      regions by CT.   Height and weight would be measured to the nearest 0.5 cm and 0.1 kg,      respectively, and BMI would be calculated (kg/m2).  Systolic and diastolic blood pressure      would be obtained after a 5-min rest; the average of the final two of three measurements      would be used in analysis. Fasting blood samples would be collected for the measurement of      glucose, insulin, LDL, HDL,25-OH vitamin D, ghrelin, adiponectin, TNF-alpha, IL-6 and high      sensitivity C-reactive protein.  Insulin resistance would be calculated via a HOMA model.      Covariates such as smoking status, physical activity, alcohol intake, sleep, and depressive      symptoms would be ascertained at baseline.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Wake Forest University Clinical Research Unit</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27157</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01350518</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20399">Assessment of abdominal fat/obesity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20414"><Endpoint>Assessment of Metabolic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><ExclusionCriteria><Exclusion disease="Obesity" id="15292"><Criterion>Subjects with BMI not Meeting Inclusion Criteria</Criterion></Exclusion><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15312">Subjects co-morbid with diabetes mellitus</SubCriterion><SubCriterion disease="Obesity" id="15313">Subjects with thyroid disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15349">Subjects on lipid modifying agents</SubCriterion><SubCriterion disease="Obesity" id="15350">Subjects with history of/scheduled to receive hormone therapy / steroid / corticosteroid</SubCriterion><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="26766"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15305">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>47.13 Months</EnrollmentPeriod><EnrollmentRate>0.64 Patients/Month</EnrollmentRate><DateFirstReceived>2011-05-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-01-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-09-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="246907"><TitleDisplay>The effect of sensory stimulation on the level of consciousness and physiological parameters</TitleDisplay><TitleOfficial>Effect of sensory stimulation programs on level of consciousness and physiological parameters in patients with head injury in intensive care units</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2014031116942N1</Identifier><Identifier type="Secondary Organisational">k/93/295</Identifier></Identifiers><Indications><Indication id="3733">Traumatic brain injury</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Sensory stimulation program</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1082027" type="Company"><TargetEntity id="5039588979" type="organizationId">Kerman University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="3733" type="ciIndication"><TargetEntity id="10060690" type="MEDDRA"/><TargetEntity id="1188" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1082027">Kerman University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2014-05-22T00:00:00Z</DateStart><DateChangeLast>2017-07-18T09:43:03Z</DateChangeLast><DateAdded>2015-12-01T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Kerman University of Medical Sciences</Affiliation><Email>shmonfared1391@gmail.com</Email><Name>Shiva Monfared parizi</Name><Phone>00983434250563 00989137148595</Phone></Contact><Contact type="Public contact"><Affiliation>Kerman University of Medical Sciences</Affiliation><Email>H_m5664@yahoo.com</Email><Name>Hakimeh Hosseirezai</Name><Phone>0098343205177 00989132406022</Phone></Contact><Contact type="Public contact"><Affiliation>Kerman University of Medical Sciences</Affiliation><Email>shmonfared1391@gmail.com</Email><Name>Shiva Monfared Parizi</Name><Phone>00 091371488595</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients diagnosed of head trauma&lt;/li&gt;&lt;li&gt;GCS&amp;lt;/= 8&lt;/li&gt;&lt;li&gt;Aged 15 to 65 years&lt;/li&gt;&lt;li&gt;The absence of sensory disorders in patients (impaired sense of hearing, sight, smell, touch and taste)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cerebral ischemia (confirmed by imaging studies)&lt;/li&gt;&lt;li&gt;Cardiac arrest &gt; 4 min after admission&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Level of consciousness: GCS and FOUR score</Description><Timeframe>Before and after each intervention</Timeframe></Measure><Measure><Description>Blood pressure: in mmHg and by cuff pressure of bed side monitoring device</Description><Timeframe>Before and after each intervention</Timeframe></Measure><Measure><Description>Heart rate: number/min and by bed side monitoring device</Description><Timeframe>Before and after each intervention</Timeframe></Measure><Measure><Description>Respiratory rate: number/min</Description><Timeframe>Before and after each intervention</Timeframe></Measure><Measure><Description>Arterial oxygen saturation: in percentage terms and by pulse oxymeter</Description><Timeframe>Before and after each intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study  is to investigate the effect of sensory stimulation program on the level of consciousness and physiological responses in patients with brain injury.&lt;br/&gt;Expected outcomes are include changes in the level of consciousness after the intervention and changes in physiological variables, including: HR, RR, o2 SAT and systolic and diastolic blood pressure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be catagorized into intervention and control groups.&lt;/para&gt;&lt;para&gt;Intervention group patients will receive  a program consisted of sensory stimulations, ie, tactile, gustatory, olfactory, auditory, visual and kinetic stimulation, five timess per day for 6 days. There will be a 2 h time interval between the interventions.&lt;/para&gt;&lt;para&gt;Control group  will have the patients affected by normal environmental stimulations and  will not receive any sensory stimulation programs.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Ali ibn Abi Talib Hospital in Rafsanjan</Name><Address1>Kerman</Address1><Contacts><Contact type="Facility contact"><Name>Shiva Monfared Parizi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2014031116942N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><DateEnrollmentEnd type="actual">2015-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>8.32 Months</EnrollmentPeriod><EnrollmentRate>7.21 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-12-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="297832"><TitleDisplay>Effectiveness of The Single-Joint HALrobot Suit</TitleDisplay><TitleOfficial>Effectiveness of The Single-Joint HAL Robot Suit For Rehabilitation After Orthopedic Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000027288</Identifier></Identifiers><Indications><Indication id="3754">Knee injury</Indication></Indications><BiomarkerNames><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Single-Joint HAL Robot Suit (HAL-SJ)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1017688" type="Company"><TargetEntity id="4296512803" type="organizationId">Fukuoka University</TargetEntity></SourceEntity><SourceEntity id="3754" type="ciIndication"><TargetEntity id="5599" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1017688">Fukuoka University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-06-01T00:00:00Z</DateStart><DateChangeLast>2017-05-17T12:38:30Z</DateChangeLast><DateAdded>2017-05-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>fukuoka university hospital ; department of rehabilitation</Affiliation><Email>goto.kyo.411@outlook.jp</Email><Name>goto kyosuke</Name><Phone>0928011011</Phone></Contact><Contact type="Scientific contact"><Affiliation>fukuoka university ; rehabilitation</Affiliation><Email>goto.kyo.411@outlook.jp</Email><Name>goto kyosuke</Name><Phone>0928011011</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Knee extension lag &gt;/= 10&lt;/li&gt;&lt;li&gt;Quad receps contraction&lt;/li&gt;&lt;li&gt;Sitting posture&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Skin disease&lt;/li&gt;&lt;li&gt;Pace maker&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Range of motion</Description><Timeframe>Post operative day 5</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Visual analog scale</Description><Timeframe>Post operative day 5</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  aim of this study is  to evaluate the feasibility of robot, assisted rehabilitation using Single-Joint HAL Robot Suit (HAL-SJ) in the early postoperative state following knee surgeries.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Eligible patients will receive HAL-SJ in experimental group . In control group patients will not use HAL-SJ.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000027288</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26067">Assessment of Feasibility</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="298282"><TitleDisplay>A study to evaluate the prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG positron emission tomography/computed tomography  in extra-nodal natural killer/T-cell lymphoma</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="311">T-cell lymphoma</Indication></Indications><BiomarkerNames><BiomarkerName id="46731" role="Therapeutic effect marker" type="Structural (imaging)">Standardized uptake value</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>18F-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Positron emission tomography/computed tomography (PET/CT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1039740" type="Company"><TargetEntity id="5035563904" type="organizationId">National Natural Science Foundation of China</TargetEntity></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"/><TargetEntity id="D016399" type="MeSH"/><TargetEntity id="-664594417" type="omicsDisease"/><TargetEntity id="704" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1039740">National Natural Science Foundation of China</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><PatientCountEnrollment>54</PatientCountEnrollment><PatientCountEvaluable>54</PatientCountEvaluable><DateChangeLast>2018-01-31T22:05:46Z</DateChangeLast><DateAdded>2017-05-18T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with extra-nodal natural killer/T-cell (NK/T) lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Progression-free survival (PFS)</Description></Measure><Measure><Description>Overall survival (OS)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to evaluate whether the sum of SUVmax of all the nodal and extra-nodal lesions (detected by 18F-FDG positron emission tomography/computed tomography  [PET/CT]) predicted progression-free survival (PFS) and/or overall survival (OS) in patients with extra-nodal natural killer/T-cell (NK/T) lymphoma [&lt;ulink linkType="Reference" linkID="1928270"&gt;1928270&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2017, results were published. Based on the basis of the sum of SUVmax of the whole-body SUVmax of 11 nodal and 10 extra-nodal lesions, three models were tested. Using time-dependent receiver-operator characteristic (ROC) curves and corresponding areas under the curve (AUC), the discrimination value of these models was evaluated in training and validation cohorts. In an independent cohort of 15 patients, findings were validated. Optimal cut-off values for WB1SUVmax, WB2SUVmax and WB3SUVmax were 15.8 (sensitivity 92%, specificity 67%, AUC 0.811; p &amp;lt; 0.001), 12.7 (sensitivity 96%; specificity 57%; AUC 0.785; p &amp;lt; 0.001) and 15.8 (sensitivity 88%; specificity 70%; AUC 0.793; p &amp;lt; 0.001) were shown by ROC curve analysis. WB3SUVmax was found to be independently associated with PFS (p = 0.023) and OS (p = 0.047) as per multivariate analyses. Significant association was observed between WB3SUVmax calculated based of the sum of the SUVmax of three nodal and ten extra-nodal lesions and PFS and OS [&lt;ulink linkType="Reference" linkID="1928270"&gt;1928270&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who underwent 18F-FDG PET/CT were included and observed [&lt;ulink linkType="Reference" linkID="1928270"&gt;1928270&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="312135"><TitleDisplay>The clinical efficacy and preliminary mechanism of electroacupuncture in treatment of postherpetic neuralgia</TitleDisplay><TitleOfficial>The clinical efficacy and preliminary mechanism of electroacupuncture in treatment of postherpetic neuralgia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-IOR-17012605</Identifier></Identifiers><Indications><Indication id="1295">Neuropathic pain</Indication></Indications><BiomarkerNames><BiomarkerName id="470" role="Therapeutic effect marker" type="Genomic;Proteomic">Brain-derived neurotrophic factor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>drugs therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>electroacupuncture</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>routine medicine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1074103" type="Company"><TargetEntity id="5037930211" type="organizationId">Guangdong Provincial Hospital of Chinese Medicine</TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"/><TargetEntity id="D009437" type="MeSH"/><TargetEntity id="-533466818" type="omicsDisease"/><TargetEntity id="14" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2017-09-06T00:00:00Z</DateStart><DateEnd type="estimated">2019-09-30T00:00:00Z</DateEnd><DateChangeLast>2017-09-15T08:25:59Z</DateChangeLast><DateAdded>2017-09-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Guangdong Provincail Hospital of Traditional Chinese Medicine</Affiliation><Email>wahahahawawa@163.com</Email><Name>YiLing Yang</Name><Phone>+86 13431049754</Phone></Contact><Contact type="Public contact"><Email>jyhf08@sina.com</Email><Name>Jianhua Liu</Name><Phone>+86 13729889452</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;According to the diagnostic standard of postherpetic neuralgia&lt;/li&gt;&lt;li&gt;Aged between 45 to 70,the duration is &gt; 3 months&lt;/li&gt;&lt;li&gt;There are stabbing, burning, cutting pain in herpes area&lt;/li&gt;&lt;li&gt;The VAS score is &gt; 4&lt;/li&gt;&lt;li&gt;There is hyperalgesia and hypersensitivity (allodynia)&lt;/li&gt;&lt;li&gt;Volunteer to participate in this study and informed consents have signed&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Some special types of shingles, such as according with brain, cornea or conjunctiva, ear involvement, disseminated herpes zoster, and visceral herpes zoster&lt;/li&gt;&lt;li&gt;Stent and pacemaker implantation in vivo, malignant tumors, neurological diseases, such as diabetes peripheral neuropathy, multiple sclerosis, spinal cord injury and other patients with serious dysfunction of heart, liver, kidney or other organs&lt;/li&gt;&lt;li&gt;The affected skin ulceration healed, rash with local bacterial or fungal infections; coagulation dysfunction&lt;/li&gt;&lt;li&gt;The women in pregnancy or lactation&lt;/li&gt;&lt;li&gt;The previous adverse reactions such as acupuncture syncope patients&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Visual analog scale</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>SF-36</Description></Measure><Measure><Description>MEP of PAS</Description></Measure><Measure><Description>BDNF</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to investigate the efficacy and explore the mechanisms of acupuncture treatment in postherpetic neuralgia patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive 2Hz EA and drugs or 100HzEA and drugs or routine medicine.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Guangdong Provincail Hospital of Traditional Chinese Medicine</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8390">Subjects with Neuropathic Pain</PatientSegment><SubSegments><SubSegment id="8392">Subjects with post herpetic neuralgia</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19391">Subjects with Symptomatic Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-IOR-17012605</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34812">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="45667"><Endpoint>Assessment of Hormone Levels</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="25898"><Endpoint>Assessment of Neuropathic Pain</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22096"><Criterion>Subjects with Neuropathic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22098">Subjects with post herpetic neuralgia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22149">Based on Visual analog scale[VAS]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22168"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20023"><Criterion>Subjects with Neuropathic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20024">Subjects with diabetic neuropathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20179"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="320712"><TitleDisplay>A study to assess the efficacy of pembrolizumab for the treatment of gestational trophoblastic disease (GTD)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="131">Gastrointestinal tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pembrolizumab</Name><Drug id="70667">pembrolizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="70667">pembrolizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="23577">Imperial College London</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="70667" type="Drug"><TargetEntity id="729094" type="siDrug">Pembrolizumab</TargetEntity></SourceEntity><SourceEntity id="23577" type="Company"><TargetEntity id="5000038184" type="organizationId">Imperial College London Ltd</TargetEntity></SourceEntity><SourceEntity id="131" type="ciIndication"><TargetEntity id="C26" type="ICD10"/><TargetEntity id="159" type="ICD9"/><TargetEntity id="10061174" type="MEDDRA"/><TargetEntity id="D005770" type="MeSH"/><TargetEntity id="-1015825676" type="omicsDisease"/><TargetEntity id="602" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23577">Imperial College London</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="67136">Programmed cell death protein 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1589">Apoptosis stimulator</Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7761">T-lymphocyte stimulator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="852">Intravesical formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>4</PatientCountEnrollment><DateChangeLast>2017-11-29T22:01:06Z</DateChangeLast><DateAdded>2017-11-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Michael Seckl</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with gestational trophoblastic disease (GTD)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In November 2017, results were presented. Patients who received pembrolizumab were found to be  well tolerated [&lt;ulink linkType="Reference" linkID="1985652"&gt;1985652&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This trial was to assess the effect of &lt;ulink linkType="Drug" linkID="70667"&gt;pembrolizumab&lt;/ulink&gt; for the treatment of gestational trophoblastic disease (GTD) [&lt;ulink linkType="Reference" linkID="1985652"&gt;1985652&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2017, results were presented. Three out of four patients with the cancerous forms of gestational trophoblastic disease (GTD) went into remission after receiving the immunotherapy with pembrolizumab. It was  found that most patients hCG levels started to fall by three doses and once their hCG was normal five consolidation doses of pembrolizumab were given before stopping treatment. The patients remain without signs of cancer recurrence for between five months to over two years on follow-up   [&lt;ulink linkType="Reference" linkID="1985652"&gt;1985652&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive pembrolizumab intravenously every 3 weeks over a period of about 6 months between 2015 to 2017  [&lt;ulink linkType="Reference" linkID="1985652"&gt;1985652&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  pembrolizumab  [&lt;ulink linkType="Reference" linkID="1985652"&gt;1985652&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Imperial College London</Name><Contacts/></Site><Site><Name>Charing Cross Hospital</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-11-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="350075"><TitleDisplay>Estimation of blood pressure using pulse transit time</TitleDisplay><TitleOfficial>Estimation of blood pressure using pulse transit time</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000033467</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="17585" role="Disease marker" type="Physiological">Pulse Wave Transit Time</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Pulse wave analysis</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>novel pressure sensor</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="28247" type="Company"><TargetEntity id="4298187527" type="organizationId">Tokyo Medical and Dental University</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28247">Tokyo Medical and Dental University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2018-08-15T00:00:00Z</DateStart><DateChangeLast>2018-08-22T11:21:42Z</DateChangeLast><DateAdded>2018-08-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tokyo Medical and Dental University ; Department of Cardiovascular Physiology</Affiliation><Email>sasano.bi@tmd.ac.jp</Email><Name>Tetsuo Sasano</Name><Phone>03-5803-5365</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tokyo Medical and Dental University ; Department of Cardiovascular Physiology</Affiliation><Email>sasano.bi@tmd.ac.jp</Email><Name>Tetsuo Sasano</Name><Phone>03-5803-5365</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy subjects with over 20 years old, who have no history of cardiovascular disease&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who have a history of syncope, QT prolongation or Brugada pattern in an electrocardiogram&lt;/li&gt;&lt;li&gt;Subjects having family history of sudden cardiac death&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Correlation between blood pressures measured by the conventional method and that using pulse transit time</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to study the efficacy of blood pressure estimation using pulse transit time with a pressure sensor.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects will receive measurement of pulse wave using a novel pressure sensor. A 120 min in maximum.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Tokyo Medical and Dental University</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="35">Others</PatientSegment><SubSegments><SubSegment id="54">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000033467</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="46164"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="114"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hypertension" id="34527"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="139">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="21"><Criterion>Subjects with abnormal ECG</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="22">Long QT syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="72"><Criterion>Subjects with history of cardiovascular disease/disorder</Criterion></Exclusion><Exclusion disease="Hypertension" id="248"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="268">Syncope or vertigo</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="271"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="358909"><TitleDisplay>Acute Effects of a Passive Stretching Session on the Mechanical Properties of Medial Gastrocnemius Muscle in Children With Cerebral Palsy</TitleDisplay><TitleOfficial>Acute Effects of a Passive Stretching Session on the Mechanical Properties of Medial Gastrocnemius Muscle in Children With Cerebral Palsy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03714269</Identifier><Identifier type="Organisational Study">18CH121</Identifier><Identifier type="Secondary Organisational">ANSM</Identifier></Identifiers><Indications><Indication id="2620">Cerebral palsy</Indication></Indications><BiomarkerNames><BiomarkerName id="17911" role="Therapeutic effect marker" type="Structural (imaging)">Muscle</BiomarkerName><BiomarkerName id="22035" role="Therapeutic effect marker" type="Structural (imaging)">Calcaneal tendon</BiomarkerName><BiomarkerName id="40660" role="Therapeutic effect marker" type="Physiological">Ankle flexion strength</BiomarkerName><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>2D ultrasound</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>isokinetic dynamometry</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>long time stretching session</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1039393" type="Company"><TargetEntity id="5035525465" type="organizationId">Centre Hospitalier Universitaire</TargetEntity></SourceEntity><SourceEntity id="2620" type="ciIndication"><TargetEntity id="G80" type="ICD10"/><TargetEntity id="10008129" type="MEDDRA"/><TargetEntity id="D002547" type="MeSH"/><TargetEntity id="-967985093" type="omicsDisease"/><TargetEntity id="163" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039393">Centre Hospitalier Universitaire de Saint Etienne</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>13</PatientCountEnrollment><DateStart>2018-10-19T00:00:00Z</DateStart><DateEnd type="actual">2018-11-28T00:00:00Z</DateEnd><DateChangeLast>2019-05-31T10:52:07Z</DateChangeLast><DateAdded>2018-11-06T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>CHU de Saint Etienne</Affiliation><Name>Vincent GAUTHERON, MD PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children with cerebral palsy of the spastic type&lt;/li&gt;&lt;li&gt;Children with a maximum dorsal ankle flexion amplitude limitation of&amp;lt; 10 deg&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Children who have undergone surgery on the lower limbs&lt;/li&gt;&lt;li&gt;Children with a botulinum toxin injection and/or a series of elongation casts for&amp;lt;   3 months&lt;/li&gt;&lt;li&gt;Children with ongoing analgesic treatment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Slope of the torque curve force - ankle joint angle in the joint area - 25 degree plantar flexion/maximum dorsal flexion</Description><Timeframe>Baseline</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Maximum dorsal flexion angle of ankle, knee in maximum extension position</Description><Timeframe>At 5 min</Timeframe></Measure><Measure><Description>Lengths of the musculotendinous unit of the triceps sural muscle, the muscular body of the gastrocnemius muscle and the achilles tendon in cm measured at rest, knee in maximum extension position, ankle angle in neutral plantar/dorsal flexion position</Description><Timeframe>At 5 min</Timeframe></Measure><Measure><Description>Slope of the force-displacement torque curve myotendinous junction of the sural triceps in the articular sector - 25 degree  plantar flexion/maximum dorsal flexion</Description><Timeframe>At 5 min</Timeframe></Measure><Measure><Description>Visual analog scale of discomfort: 0 = not discomfort and 10 = maximal discomfort</Description><Timeframe>At 5 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of  this study was to  assess the  efficacy of an acute high      intensity and long-time stretching session of plantarflexors muscle on their viscoelasticity      properties and maximal dorsiflexion angle gain. Single stretching session was characterized by      high intensity and long time (5 min).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Children with cerebral palsy of  the spastic type   would be  included in this study. The patients would undergo a measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer. Measurement evaluated with an 2D ultrasound include simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during five  passive mobilization cycles of ankle flexion-extension at very low speed,and recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction. An assessment of the level of discomfort would include visual analog scale (0 = no discomfort and 10 = maximal discomfort).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>CHU de Saint Etienne</Name><Address1>Saint Etienne</Address1><Address3>42055</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16683">Others</PatientSegment><SubSegments><SubSegment id="16704">Children and adolescents</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16210">Subjects with Cerebral Palsy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03714269</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other neurological disease" id="43215"><Endpoint>Imaging/Radiological Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32590"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32975">Subjects co-morbid with cerebral palsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32903">Children and adolescents</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24402"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24408"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="27436"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-11-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-10-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-11-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-31T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-31T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-31T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="359876"><TitleDisplay>Effectiveness of Dry Needling of the Sternocleidomastoid in Patients With Cervicogenic Headaches</TitleDisplay><TitleOfficial>Effectiveness of Dry Needling of the Sternocleidomastoid in Patients With Cervicogenic Headaches - A Randomized Clinical Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03730896</Identifier><Identifier type="Organisational Study">FGCU IRB 2018-49</Identifier></Identifiers><Indications><Indication id="148">Headache</Indication></Indications><BiomarkerNames><BiomarkerName id="46479" role="Therapeutic effect marker" type="Physiological">Cervical motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dry needling</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>normal manual therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1037595" type="Company"><TargetEntity id="5035425778" type="organizationId">Florida Gulf Coast University</TargetEntity></SourceEntity><SourceEntity id="148" type="ciIndication"><TargetEntity id="R51" type="ICD10"/><TargetEntity id="784.0" type="ICD9"/><TargetEntity id="10019211" type="MEDDRA"/><TargetEntity id="D006261" type="MeSH"/><TargetEntity id="-843303252" type="omicsDisease"/><TargetEntity id="25" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037595">Florida Gulf Coast University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>64</PatientCountEnrollment><DateStart>2018-10-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-03-01T00:00:00Z</DateEnd><DateChangeLast>2018-11-16T06:15:51Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>rsillevis@fgcu.edu</Email><Name>Rob Sillevis, PhD</Name><Phone>239-257-1431</Phone></Contact><Contact type="Scientific contact"><Affiliation>FGCU Assistent Professor</Affiliation><Name>Rob Sillevis, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Integrated therapy Practice PC</Affiliation><Name>Karen Wyss, DPT</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 18 to 65 years old&lt;/li&gt;&lt;li&gt;Primary complaint of cervicogenic headache&lt;/li&gt;&lt;li&gt;Restricted cervical Range of motion&lt;/li&gt;&lt;li&gt;Neck Disability Index&amp;gt; 20 points&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Red flags identified during the patients physical therapy initial evaluation (ie, tumor, fracture, metabolic diseases, RA, osteoporosis, prolonged history of steroid use, symptoms of vertebrobasilary insufficiency, pregnancy, cervical spinal stenosis, bilateral upper extremity symptoms etc&lt;/li&gt;&lt;li&gt;Use of blood thinners&lt;/li&gt;&lt;li&gt;History of whiplash injury within the past 6 weeks&lt;/li&gt;&lt;li&gt;Evidence of central nervous system involvement, to include hyperreflexia, sensory disturbances in the hand, intrinsic muscle wasting of the hands, unsteadiness during walking, nystagmus, loss of visual acuity, impaired sensation of the face, altered taste, the presence of pathological reflexes (ie, positive Hoffman's and/or Babinski reflexes), etc&lt;/li&gt;&lt;li&gt;Two or more positive neurological signs consistent with nerve root compression, including any two of the following:&lt;ul&gt;&lt;li&gt;Muscle weakness involving a major muscle group of the upper extremity&lt;/li&gt;&lt;li&gt;Diminished upper extremity muscle stretch reflex (biceps brachii, brachioradialis, or triceps)&lt;/li&gt;&lt;li&gt;Diminished or absent sensation to pinprick in any upper extremity dermatome&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior surgery to the neck or thoracic spine&lt;/li&gt;&lt;li&gt;Chiropractic, Physical Therapy, or Acupuncture treatment for their neck pain in the last 6-months&lt;/li&gt;&lt;li&gt;Workers compensation or pending legal action regarding their headaches&lt;/li&gt;&lt;li&gt;Insufficient English language skills to complete all questionnaires&lt;/li&gt;&lt;li&gt;Inability to comply with treatment and follow-up schedule&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in Headache Disability Index (HDI) score: questionnaire for self report, this will be on a 0 to 100 score</Description><Timeframe>At initial evaluation (day 1), week three (day 21) and week 6 (day 42)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in cervical range of motion using an inclinometer/change in high cervical range of motion using the Flexion-Rotation Test (FRT): range of motion assessment, this will be measured in degrees with standardized goniometer measure</Description><Timeframe>At initial evaluation (day 1), week three (day 21) and week 6 (day 42)</Timeframe></Measure><Measure><Description>Change in the neck disability Index score: self report neck pain questionnaire, This is a 0 to 100 score</Description><Timeframe>At initial evaluation (day 1), week three (day 21) and week 6 (day 42)</Timeframe></Measure><Measure><Description>Change in visual analog scale score: pain intensity scale, on a 10 cm line patient is asked to mark pain with one vertical mark</Description><Timeframe>At initial evaluation (day 1), week three (day 21) and week 6 (day 42)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study aims to evaluate the benefit of dry needling of the sternocleidomastoid muscle in subjects with      cervicogenic headaches. The purpose of this study is to determine whether individuals with cervicogenic headache      respond favorably to a program of manual therapy in combination with dry needling of the      major muscle between chest bone and the head (sternocleidomastoid muscle) compared to manual      therapy directed to the upper body quadrant alone.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The researchers will conduct a randomized clinical trial to assess the effectiveness of a      manual therapy and dry needling approach (group 1) versus manual therapy only (group 2):&lt;br/&gt;Group 1: clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment.&lt;br/&gt;Group 2: clinician will decide normal course of treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Integrated therapy Practice PC</Name><Address1>Hobart</Address1><Address2>Indiana</Address2><Address3>46342</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>meywyss@comcast.net</Email><Name>Karen Wyss, DPT</Name><Phone>219-945-1538</Phone></Contact><Contact type="Facility investigator"><Name>Karen Wyss, DPT</Name></Contact><Contact type="Facility investigator"><Name>Rob Sillevis, PHD</Name></Contact><Contact type="Facility investigator"><Name>Arie van Duijn, EdD</Name></Contact><Contact type="Facility investigator"><Name>Jacqueline van Duijn, DPT</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03730896</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25970">Assessment by Headache Disability Index</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25969">Assessment by Neck Disability Index</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22120"><Criterion>Subjects with Other Headaches</Criterion></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22178">Subjects with pre-specified functional assessments</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26026"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Pain" id="20168">Subjects with history/scheduled for surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="28333"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-02-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-10-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="376613"><TitleDisplay>Functional Parameters Indicative of Heart Failure</TitleDisplay><TitleOfficial>Functional Parameters Indicative of Heart Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03909919</Identifier><Identifier type="Organisational Study">FUNNEL STUDY</Identifier></Identifiers><Indications><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="159" role="Disease marker" type="Biochemical">Lactic Acid</BiomarkerName><BiomarkerName id="1904" role="Disease marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="40644" role="Disease marker" type="Physiological">Muscle echo intensity</BiomarkerName><BiomarkerName id="53115" role="Disease marker" type="Structural (imaging)">Quadriceps muscle</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard care</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="23507" type="Company"><TargetEntity id="4296365401" type="organizationId">King's College London</TargetEntity></SourceEntity><SourceEntity id="29785" type="Company"><TargetEntity id="5035530341" type="organizationId">University Of Malaga</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29785">University of Malaga</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23507">King's College London</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>34</PatientCountEnrollment><DateStart>2019-06-27T00:00:00Z</DateStart><DateEnd type="estimated">2020-10-10T00:00:00Z</DateEnd><DateChangeLast>2019-05-10T09:49:44Z</DateChangeLast><DateAdded>2019-04-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>acuesta@uma.es</Email><Extension>+34</Extension><Name>Antonio Cuesta Vargas, PhD</Name><Phone>952137551</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Malaga</Affiliation><Name>Dr. Antonio I Cuesta-Vargas</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects &gt; 70 years&lt;/li&gt;&lt;li&gt;Healthy subjects and subjects diagnosed with heart failure&lt;/li&gt;&lt;li&gt;Subjects able of filling out questionnaires and performing functional tests&lt;/li&gt;&lt;li&gt;Subjects who are in a clinical stability and optimal treatment phase&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participants with cardiac pathologies other than heart failure&lt;/li&gt;&lt;li&gt;Score in the NYHA scale = 4&lt;/li&gt;&lt;li&gt;Hospitalization in a period of time&amp;lt;/= 3 months&lt;/li&gt;&lt;li&gt;Score on the Mini-Mental scale&amp;lt; 24&lt;/li&gt;&lt;li&gt;Inability to get up from the chair at least five times or 30 s&lt;/li&gt;&lt;li&gt;Inability to walk for 6 min&lt;/li&gt;&lt;li&gt;Inability to walk independently without a walking assistance device (cane, crutch or walker)&lt;/li&gt;&lt;li&gt;Subjects participating in an experimental study where they receive a treatment&lt;/li&gt;&lt;li&gt;Inability to provide informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Motion parameters: kinematic parameters will be analyzed using an inertial sensor included in the Shimmer3 instrument during the performance of different functional task</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Kinematic analysis by 3D motion capture: a camera will perform a motion capture of the functional task. This system will calculate the displacement and the time of the functional task</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Responsiveness: the responsiveness Box of COSMIN checklist will be used to determinate the response to change of the Shimmer 3 Inertial Sensor and the 3D cameras. All possible items will be followed</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Reliability: the Reliability Box of COSMIN checklist will be used to determinate the test-retest reliability of the Shimmer3 Inertial Sensor and the 3D cameras. All possible items will be followed</Description><Timeframe>1 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cardiopulmonary function: the heart rate will be assessed using the ECG Unit of Shimmer3</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Metabolic parameters: the blood lactate produced will be analyzed using the Lactate Pro 2 blood lactate analyzer</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Quadriceps muscle echo-intensity: muscle echo-intensity will be analysed using the B-mode ultrasonography device (SonoSite 180 Plus, SonoSite Japan, Tokyo, Japan)</Description><Timeframe>15 min</Timeframe></Measure><Measure><Description>Quadriceps penile angle: the penile angle will be analysed using the B-mode ultrasonography device (SonoSite 180 Plus, SonoSite Japan, Tokyo, Japan)</Description><Timeframe>15 min</Timeframe></Measure><Measure><Description>Quadriceps thickness: muscular thickness will be analysed using the B-mode ultrasonography device (SonoSite 180 Plus, SonoSite Japan, Tokyo, Japan)</Description><Timeframe>15 min</Timeframe></Measure><Measure><Description>SARC-F: it is a simple questionnaire to rapidly diagnose sarcopenia. It is composed by five components: strength, assistance to walk, get up from a chair, climb stairs and falls. Scores range from 0 to 10, with 0 to 2 points for each component. A score &gt;/= 4 could predict sarcopenia and poor results</Description><Timeframe>10 min</Timeframe></Measure><Measure><Description>Abbreviated comprehensive geriatric assessment (aCGA): a questionnaire formed by items originating from four different scales: questionnaire used to assess functional, emotional and cognitive components. It is composed of 15 items from the four instruments such as the geriatric depression scale (GDS), the Mini-Mental State Examination (MMSE), activities of daily living (ADL) using the Katz index and instrumental activities of daily living (IADL) using the Lawnton and Brody scale. The score varies from 0 to 30 points, giving 1 point to each of the items of the GDS (4 points in total), 12 to the three items from the scale of Lawton and Brody, 8 points to the four items from the MMSE and 6 points to the three items from the Katz index</Description><Timeframe>15 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The present study aims to develop an index formed by the variables, functional tests, scales      and instruments that best discriminate between healthy subjects and subjects with heart      failure (HF) and that allows the stratification of different levels of severity of HF, and to      validate new systems that allow the movement analysis for the early diagnosis of subjects      with heart failure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study will consists of two arms. Heart failure subjects  diagnosed with heart failure, who will receive the best treatment of clinical practice, will be recruited  in arm 1. They will be of age &amp;gt; 70 years. The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the standard care. Arm 2 will consist of healthy /match control healthy subjects of the same age as people with heart failure. Functional parameters will be analyzed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>University of Malaga</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="13416">Subjects with NYHA Functional Class	</PatientSegment><SubSegments><SubSegment id="75">Mild /NYHA Functional Class I/Asymptomatic Heart Failure Subjects</SubSegment><SubSegment id="76">Mild /NYHA Functional Class II Heart Failure Subjects</SubSegment><SubSegment id="77">Moderate/NYHA Functional Class III Heart Failure Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="15275">Others</PatientSegment><SubSegments><SubSegment id="18687">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03909919</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="28679"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="45160"><Endpoint>Assessment of Clinical Response</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="662"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="785">Heart rate variability (HRV) measures</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="708"><Endpoint>Assessment of Electrocardiography (ECG) Findings</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="2147">Morbidity</SubEndpoint><SubEndpoint disease="Cardiac failure" id="2149">Muscle Strength and Muscle Mass</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1203"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="6794"><Endpoint>Assessment of Non Cardiovascular  Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="970">Metabolic events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="28679"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28703">Assessment by Activities of Daily Living scale (ADL)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="44576"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28709">Assessment by Geriatric Depression Scale (GDS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="45693"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28706">Assessment by Mini-Mental State Examination (MMSE)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="456">Subjects with stable medical conditions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="31870"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="274">Subjects with heart failure, NYHA class I</SubCriterion><SubCriterion disease="Cardiac failure" id="275">Subjects with heart failure, NYHA class II</SubCriterion><SubCriterion disease="Cardiac failure" id="276">Subjects with heart failure, NYHA class III</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34526"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="446">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34921"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="499">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="469"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="679"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="763">Subjects unable to walk without personal aid</SubCriterion><SubCriterion disease="Cardiac failure" id="802">Recent/current hospitalization</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="22578"><Criterion>Subjects with NYHA Functional Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="434">Subjects with NYHA functional class IV</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25524"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="728">Inability to give valid informed consent</SubCriterion><SubCriterion disease="Cardiac failure" id="795">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27844"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="823">Unwillingness/inability to comply with study requirements/protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-10-15T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-04-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-05-13T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="removed"><Date>2019-05-13T00:00:00Z</Date><Reason id="321">Trial Biomarker Removed</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>